FDA Approves GLP-1 Wegovy To Reduce Risk Of Serious Heart Problems In Adults With Obesity Or Overweight

The U.S. Food and Drug Administration (FDA) approved a new indication for use of Wegovy (semaglutide) injection to reduce the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and either obesity or overweight. Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. In June 2021, Wegovy was approved by the FDA as a treatment for weight loss for adults with obesity and for adults with overweight who have at least one weight-related comorbid condition.

The new approval was based on the outcomes of a multi-national, multi-center, placebo-controlled double . . .